title: Preclinical models of pediatric solid tumors (neuroblastoma) and their use in drug discovery.
abstract: Neuroblastoma is the most common pediatric abdominal solid tumor. This aggressive embryonal malignancy of neural crest origin has a peak age of onset of 22 months, and accounts for ~11% of all pediatric cancers and 15% of all pediatric cancer deaths. With current treatment protocols, including high-dose chemotherapy with autologous stem cell transplantation, radiation, and surgery, ~80% of high-risk patients go into remission, although the majority relapse and succumb to therapy-resistant tumors. Long-term survival rates (>5 years) are <50%. Mouse models of neuroblastoma provide clinically relevant tools for studying the growth and metastasis of this aggressive malignancy, and for testing the efficacy of potentially novel therapeutics in vivo. This unit describes an orthotopic murine model of neuroblastoma using cultured human cells that closely mimics the clinical condition in terms of the bulky intra-abdominal tumors and other aspects of metastatic disease. Also described are methods for in vivo imaging and monitoring of tumor growth, and procedures for necropsy and tumor preservation for pathological analysis.
authors.affiliation: Baylor College of Medicine, Texas Children's Hospital, Houston, Texas, USA.
authors.forename: Danielle M
authors.initials: DM
authors.lastname: Patterson
authors.forename: Jason M
authors.initials: JM
authors.lastname: Shohet
authors.forename: Eugene S
authors.initials: ES
authors.lastname: Kim
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000818:Animals; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D000068258:Bevacizumab; D002648:Child; D004195:Disease Models, Animal; D055808:Drug Discovery / Q000379:methods*; D006801:Humans; D007223:Infant; D049449:Luminescence; D051379:Mice; D009447:Neuroblastoma / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology*; D014407:Tumor Cells, Cultured; D051598:Whole Body Imaging / Q000379:methods
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab